NEMARKO: Cerebral Oxymetry and Neuronal Markers in Newborns and Infants Undergoing Surgery

Sponsor
Lithuanian University of Health Sciences (Other)
Overall Status
Completed
CT.gov ID
NCT02423369
Collaborator
Research Council of Lithuania (Other)
49
1
1
32
1.5

Study Details

Study Description

Brief Summary

The purpose of this study is to assess whether peri-operative period in neonates and infants is associated with an increase in blood biomarkers, specific for neuronal injury, and to correlate them with clinical variables and sedative/analgesic agents. Patients, who meet inclusion criteria and does not meet exclusion criteria, are enrolled. Blood samples for measurement serum concentrations of markers (S100-B and Neuron-Specific Enolase (NSE)) are drawn before surgery (baseline) and on the 1-st, 2-nd and 3-rd day after surgery. During surgery cerebral oxygenation (rSO2) monitoring is continuously applied; rSO2, hemodynamic and respiratory values are simultaneously recorded every 5 minutes. Anesthesia, pre and postoperative treatment, including analgesia and sedation, are given as per standard of care.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Cerebral near infrared spectroscopy
  • Other: S-100B protein in serum
  • Other: NSE protein in serum
N/A

Detailed Description

Retrospective studies have shown that surgery in infancy is associated with worse neurodevelopmental outcome, compared to general population. The reasons may be complex, and patients at risk are unknown. Brain growth and central nervous system formation are extremely active in neonates and infants. Metabolic or circulatory derangement may have negative influence on the developing brain. Disease and perioperative period, both may further put this population at risk for physiological abnormalities. Near infrared spectroscopy was shown to be a convenient method for monitoring of cerebral tissue oxygenation during surgery.

The great majority of anesthetics and sedative drugs, used in perioperative period, were shown to cause neuronal apoptosis in experimental animals. Some studies found that neurological marker S-100B increased in cerebrospinal fluid and blood immediately following anesthesia in animals. Several clinical studies supported this founding in children following cardiac and general surgery.

The aim of this study is to assess the dynamics of S-100B protein pre- and during 72 hours after surgery in neonates and infants aged 1-93 days, operated for abdominal/thoracic/urologic malformations/disease. As S-100B in blood may have extracranial sources, we simultaneously assess other neuronal marker Neuron-specific Enolase.

Study Design

Study Type:
Interventional
Actual Enrollment :
49 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Cerebral Oxymetry and Neuronal Biomarkers in Newborns and Infants During Perioperative Period
Study Start Date :
Mar 1, 2013
Actual Primary Completion Date :
Nov 1, 2015
Actual Study Completion Date :
Nov 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: neonates and infants requiring surgery

neonates and infants in whom blood samples for measurement of S-100 B protein in serum and NSE protein in serum are taken pre-operatively and 1-st, 2-nd and 3-rd post-operatively. During anesthesia cerebral near infrared spectroscopy is continuously applied until the wound closure.

Procedure: Cerebral near infrared spectroscopy
At the start of anesthesia on the patient's forehead two electrodes are attached the for continuous measurement of cerebral near infrared spectroscopy during surgery.
Other Names:
  • cerebral tissue oxygen saturation
  • cerebral oxymetry
  • Other: S-100B protein in serum
    0,5-1 ml of blood from periferal site for determination of serum S-100B concentration.
    Other Names:
  • S-100B protein in blood
  • Other: NSE protein in serum
    0,5-1 ml of blood from periferal site for determination of serum NSE concentration.
    Other Names:
  • Neuron-specific Enolase in blood
  • Outcome Measures

    Primary Outcome Measures

    1. change in S-100B and NSE concentrations in serum [within 24 hours and 3 days after surgery]

      change in S-100B and NSE concentrations in serum compared to preoperative value

    Secondary Outcome Measures

    1. association of S-100B and NSE concentrations in serum with intraoperative cerebral near infrared spectroscopy values. [within 24 hours after surgery]

    Other Outcome Measures

    1. association of S-100B and NSE concentrations in serum with cumulative doses of sedative agents [within 24 hours pre surgery to 3 days after surgery]

      Pre and postoperative S-100B and NSE concentrations in serum will be correlated with the administered pre and postoperative cumulative doses of sedatives and analgesics

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A to 93 Days
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • patients, undergoing general, thoracic, urological surgery for congenital anomalies or disease

    • signed written informed consent by parents/official caregivers

    Exclusion Criteria:
    • cardiac surgery

    • any evidence of neurological disease

    • sepsis

    • limited ability to obtain blood samples

    • clinically significant anemia

    • physical status of the patients corresponding to American Society of Anesthesiologists (ASA) class 4 and 5.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Lithuanian University of Health Sciences Kaunas Clinics Kaunas Lithuania 50009

    Sponsors and Collaborators

    • Lithuanian University of Health Sciences
    • Research Council of Lithuania

    Investigators

    • Principal Investigator: Danguole C Rugyte, MD. PhD, Lithuanian University of Health Sciences

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Danguole C Rugyte, MD, PhD., Lithuanian University of Health Sciences
    ClinicalTrials.gov Identifier:
    NCT02423369
    Other Study ID Numbers:
    • BE-2-43
    First Posted:
    Apr 22, 2015
    Last Update Posted:
    Dec 15, 2015
    Last Verified:
    Dec 1, 2015
    Keywords provided by Danguole C Rugyte, MD, PhD., Lithuanian University of Health Sciences

    Study Results

    No Results Posted as of Dec 15, 2015